62 related articles for article (PubMed ID: 25397567)
1. The impact of nevirapine- versus protease inhibitor-based regimens on virological markers of HIV-1 persistence during seemingly suppressive ART.
Kiselinova M; Anna M; Malatinkova E; Vervish K; Beloukas A; Messiaen P; Bonczkowski P; Trypsteen W; Callens S; Verhofstede C; De Spiegelaere W; Vandekerckhove L
J Int AIDS Soc; 2014; 17(4 Suppl 3):19823. PubMed ID: 25397567
[TBL] [Abstract][Full Text] [Related]
2. HIV-1 RNA and HIV-1 DNA persistence during suppressive ART with PI-based or nevirapine-based regimens.
Kiselinova M; Geretti AM; Malatinkova E; Vervisch K; Beloukas A; Messiaen P; Bonczkowski P; Trypsteen W; Callens S; Verhofstede C; De Spiegelaere W; Vandekerckhove L
J Antimicrob Chemother; 2015 Dec; 70(12):3311-6. PubMed ID: 26324076
[TBL] [Abstract][Full Text] [Related]
3. Ultrasensitive assessment of residual HIV viraemia in HAART-treated patients with persistently undetectable plasma HIV-RNA: a cross-sectional evaluation.
Bonora S; Nicastri E; Calcagno A; Gonzalez de Requena D; D'Ettorre G; Sarmati L; Palmisano L; Vullo V; Di Perri G; Andreoni M
J Med Virol; 2009 Mar; 81(3):400-5. PubMed ID: 19152404
[TBL] [Abstract][Full Text] [Related]
4. Nevirapine-raltegravir combination, an NRTI and PI/r sparing regimen, as maintenance antiretroviral therapy in virologically suppressed HIV-1-infected patients.
Reliquet V; Chirouze C; Allavena C; Muret P; Peytavin G; André-Garnier E; Bettinger D; Ferré V; Hoen B; Raffi F
Antivir Ther; 2014; 19(1):117-23. PubMed ID: 24145365
[TBL] [Abstract][Full Text] [Related]
5. Switch to raltegravir-based regimens and HIV DNA decrease in patients with suppressed HIV RNA.
Bianco C; Meini G; Rossetti B; Lamonica S; Mondi A; Belmonti S; Fanti L; Ciccarelli N; Di Giambenedetto S; Zazzi M; De Luca A
J Int AIDS Soc; 2014; 17(4 Suppl 3):19791. PubMed ID: 25397535
[TBL] [Abstract][Full Text] [Related]
6. Effectiveness of efavirenz compared with ritonavir-boosted protease-inhibitor-based regimens as initial therapy for patients with plasma HIV-1 RNA above 100,000 copies/ml.
Imaz A; Llibre JM; Navarro J; Curto J; Clotet B; Crespo M; Ferrer E; Saumoy M; Tiraboschi JM; Murillo O; Podzamczer D
Antivir Ther; 2014; 19(6):569-77. PubMed ID: 24458091
[TBL] [Abstract][Full Text] [Related]
7. Standard-dose efavirenz vs. standard-dose nevirapine in antiretroviral regimens among HIV-1 and tuberculosis co-infected patients who received rifampicin.
Manosuthi W; Mankatitham W; Lueangniyomkul A; Chimsuntorn S; Sungkanuparph S
HIV Med; 2008 May; 9(5):294-9. PubMed ID: 18400076
[TBL] [Abstract][Full Text] [Related]
8. Nevirapine use, prolonged antiretroviral therapy and high CD4 nadir values are strongly correlated with undetectable HIV-DNA and -RNA levels and CD4 cell gain.
Sarmati L; Parisi SG; Montano M; Andreis S; Scaggiante R; Galgani A; Viscione M; Maffongelli G; Ricciardi A; Andreoni C; Boros S; Palù G; Andreoni M
J Antimicrob Chemother; 2012 Dec; 67(12):2932-8. PubMed ID: 22915460
[TBL] [Abstract][Full Text] [Related]
9. Characterization of associations and development of atazanavir resistance after unplanned treatment interruptions.
Tinago W; O'Halloran JA; O'Halloran RM; Macken A; Lambert JS; Sheehan GJ; Mallon PW
HIV Med; 2014 Apr; 15(4):224-32. PubMed ID: 24215370
[TBL] [Abstract][Full Text] [Related]
10. Switching from suppressive protease inhibitor-based regimens to nevirapine-based regimens: a meta-analysis of randomized controlled trials.
Ena J; Leach A; Nguyen P
HIV Med; 2008 Oct; 9(9):747-56. PubMed ID: 18651856
[TBL] [Abstract][Full Text] [Related]
11. Cellular HIV-1 DNA quantification and short-term and long-term response to antiretroviral therapy.
Masquelier B; Taieb A; Reigadas S; Marchou B; Cheneau C; Spire B; Charpentier C; Leport C; Raffi F; Chêne G; Descamps D;
J Antimicrob Chemother; 2011 Jul; 66(7):1582-9. PubMed ID: 21525020
[TBL] [Abstract][Full Text] [Related]
12. Cellular HIV-1 DNA quantitation in patients during simplification therapy with protease inhibitor-sparing regimens.
Sarmati L; Parisi SG; Nicastri E; d'Ettorre G; Andreoni C; Dori L; Gatti F; Montano M; Buonomini AR; Boldrin C; Palù G; Vullo V; Andreoni M
J Med Virol; 2007 Jul; 79(7):880-6. PubMed ID: 17516532
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness and safety of protease inhibitor-based regimens in HIV-infected Thai children failing first-line treatment.
Wattanutchariya N; Sirisanthana V; Oberdorfer P
HIV Med; 2013 Apr; 14(4):226-32. PubMed ID: 23094820
[TBL] [Abstract][Full Text] [Related]
14. Predictors of virological outcome and safety in primary HIV type 1-infected patients initiating quadruple antiretroviral therapy: QUEST GW PROB3005.
Hoen B; Cooper DA; Lampe FC; Perrin L; Clumeck N; Phillips AN; Goh LE; Lindback S; Sereni D; Gazzard B; Montaner J; Stellbrink HJ; Lazzarin A; Ponscarme D; Staszewski S; Mathiesen L; Smith D; Finlayson R; Weber R; Wegmann L; Janossy G; Kinloch-de Loes S;
Clin Infect Dis; 2007 Aug; 45(3):381-90. PubMed ID: 17599319
[TBL] [Abstract][Full Text] [Related]
15. Does an increase in nevirapine plasma levels cause complete virologic suppression in patients experiencing early virologic failure?
de Requena DG; Núñez M; Gallego O; Jiménez-Nácher I; González-Lahoz J; Soriano V
HIV Clin Trials; 2002; 3(6):463-7. PubMed ID: 12501129
[TBL] [Abstract][Full Text] [Related]
16. Integrated and Total HIV-1 DNA Predict Ex Vivo Viral Outgrowth.
Kiselinova M; De Spiegelaere W; Buzon MJ; Malatinkova E; Lichterfeld M; Vandekerckhove L
PLoS Pathog; 2016 Mar; 12(3):e1005472. PubMed ID: 26938995
[TBL] [Abstract][Full Text] [Related]
17. Prevalence and risk factors for developing K65R mutations among HIV-1 infected patients who fail an initial regimen of fixed-dose combination of stavudine, lamivudine, and nevirapine.
Sungkanuparph S; Manosuthi W; Kiertiburanakul S; Saekang N; Pairoj W; Chantratita W
J Clin Virol; 2008 Apr; 41(4):310-3. PubMed ID: 18316243
[TBL] [Abstract][Full Text] [Related]
18. Factors Associated With Persistence of Plasma HIV-1 RNA During Long-term Continuously Suppressive Firstline Antiretroviral Therapy.
Ruggiero A; Cozzi-Lepri A; Beloukas A; Richman D; Khoo S; Phillips A; Geretti AM;
Open Forum Infect Dis; 2018 Feb; 5(2):ofy032. PubMed ID: 29507867
[TBL] [Abstract][Full Text] [Related]
19. Switching to nevirapine-based regimens after undetectable viral load is not associated with increased risk of discontinuation due to toxicity.
Patterson P; Socías E; Pryluka D; Lapadula P; Pérez H; Cahn P
J Int AIDS Soc; 2014; 17(4 Suppl 3):19794. PubMed ID: 25397538
[TBL] [Abstract][Full Text] [Related]
20. Nevirapine and efavirenz elicit different changes in lipid profiles in antiretroviral-therapy-naive patients infected with HIV-1.
van Leth F; Phanuphak P; Stroes E; Gazzard B; Cahn P; Raffi F; Wood R; Bloch M; Katlama C; Kastelein JJ; Schechter M; Murphy RL; Horban A; Hall DB; Lange JM; Reiss P
PLoS Med; 2004 Oct; 1(1):e19. PubMed ID: 15526045
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]